Overview

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Antibodies, Monoclonal